Baxter International INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NYSE
Baxter International Inc. reports a challenging 2025 with significant leadership changes and strategic divestitures, as it embarks on a turnaround strategy.
NYSE
Baxter International Inc. announces its 2025 Annual Meeting and provides details on voting procedures and proposals.
NYSE
Baxter International completed the sale of its Kidney Care business and announced leadership changes as part of a strategic transformation.
NYSE
DEFA14A: Baxter International Updates Proxy Statement Regarding Broker Non-Votes for 2024 Annual Meeting
Baxter International Inc. has issued a supplement to its proxy statement clarifying the impact of broker non-votes on certain proposals at the upcoming 2024 Annual Meeting of Stockholders.
NYSE
DEFA14A: Baxter International Inc. Sets Date for 2024 Annual Meeting, Outlines Proposals for Stockholder Vote
Baxter International Inc. announces its 2024 Annual Meeting and provides details on proposals for stockholder voting, including the election of directors, executive compensation, and amendments to the incentive plan and corporate charter.
NYSE
Baxter International is targeting the second half of 2024 for the separation of its Kidney Care business, alongside other strategic initiatives to enhance operational effectiveness and shareholder value.